Parse Biosciences and Codebreaker Labs launched a collaboration to couple Codebreaker’s engineered variant libraries with Parse’s single-cell transcriptomics to determine how genetic variants affect single-cell gene expression. The partnership aims to generate experimental datasets to improve whole-genome interpretation, target discovery and precision clinical-trial design. Financial terms were not disclosed; Qiagen is in the process of acquiring Parse for up to $280 million. The joint platform will enable higher-throughput functional annotation of rare variants by linking engineered perturbations to cell-state changes at single-cell resolution — a dataset class that could feed AI models and drug target validation pipelines.